Vault-13

ACUTA CAPITAL PARTNERS, LLC

REDWOOD CITY, CA · CIK 1582844 · 13F filing filed 2022-08-15

No investment adviser registration (Form ADV) found for this filer. It may be a parent company whose subsidiaries are the registered advisers, a bank or insurer, or a manager based outside the US.

$178.8m reported value -14.9% vs Q1 2022
41positions
60.5%in top 10
12 new 12 added 10 reduced 9 sold out vs Q1 2022

Options: 2 call positions ($694.0k notional), 0 put positions (— notional) – listed below, not included above.

Holdings, Q2 2022

The small lines show how much was held over the last 4 quarters (adjusted for stock splits).

#SecurityTickerShares Value% of portfolioChangeShares change
1 APELLIS PHARMACEUTICALS INC COM APLS APLS 554,000 $25.1m14.01% 14.01% UnchangedShares held: Q3 2021 75.5k, Q4 2021 535.0k, Q1 2022 554.0k, Q2 2022 554.0k
2 AADI BIOSCIENCE INC COM WHWK WHWK 1,529,402 $18.8m10.54% 10.54% UnchangedShares held: Q3 2021 1.5m, Q4 2021 1.5m, Q1 2022 1.5m, Q2 2022 1.5m
3 VISTAGEN THERAPEUTICS INC COM NEW VTGN VTGN 11,361,451 $10.0m5.59% 5.59% ReducedShares held: Q3 2021 11.7m, Q4 2021 11.7m, Q1 2022 11.7m, Q2 2022 11.4m -374.8k -374,832 -3.2%
4 KURA ONCOLOGY INC COM KURA KURA 536,500 $9.8m5.50% 5.50% AddedShares held: Q3 2021 291.9k, Q4 2021 291.9k, Q1 2022 474.0k, Q2 2022 536.5k +62.5k +62,531 13.2%
5 BCLS ACQUISITION CORP COM CL A COM CL A 843,122 $8.3m4.67% 4.67% UnchangedShares held: Q3 2021 843.1k, Q4 2021 843.1k, Q1 2022 843.1k, Q2 2022 843.1k
6 XENON PHARMACEUTICALS INC COM XENE XENE 272,500 $8.3m4.64% 4.64% AddedShares held: Q3 2021 417.4k, Q4 2021 225.0k, Q1 2022 225.0k, Q2 2022 272.5k +47.5k +47,500 21.1%
7 BELLUS HEALTH INC NEW COM NEW BLU BLU 816,000 $7.5m4.22% 4.22% UnchangedShares held: Q3 2021 2.0m, Q4 2021 525.0k, Q1 2022 816.0k, Q2 2022 816.0k
8 CELLDEX THERAPEUTICS INC NEW COM NEW CLDX CLDX 267,195 $7.2m4.03% 4.03% ReducedShares held: Q3 2021 337.5k, Q4 2021 340.1k, Q1 2022 322.9k, Q2 2022 267.2k -55.7k -55,703 -17.2%
9 RELMADA THERAPEUTICS INC COM RLMD RLMD 352,500 $6.7m3.74% 3.74% AddedShares held: Q3 2021 0, Q4 2021 404.0k, Q1 2022 342.0k, Q2 2022 352.5k +10.5k +10,500 3.1%
10 MIRATI THERAPEUTICS INC COM MRTX MRTX 94,500 $6.3m3.55% 3.55% AddedShares held: Q3 2021 0, Q4 2021 20.0k, Q1 2022 52.5k, Q2 2022 94.5k +42.0k +42,000 80.0%
11 JIYA ACQUISITION CORP COM CL A COM CL A 562,500 $5.6m3.11% 3.11% UnchangedShares held: Q3 2021 562.5k, Q4 2021 562.5k, Q1 2022 562.5k, Q2 2022 562.5k
12 IVERIC BIO INC COM OPHT OPHT 563,607 $5.4m3.03% 3.03% AddedShares held: Q3 2021 1.1m, Q4 2021 470.0k, Q1 2022 539.5k, Q2 2022 563.6k +24.1k +24,107 4.5%
13 ROCHE GS COM COM 16,000 $5.3m2.99% 2.99% NewShares held: Q3 2021 0, Q4 2021 0, Q1 2022 0, Q2 2022 16.0k
14 ARCUS BIOSCIENCES INC COM RCUS RCUS 167,500 $4.2m2.37% 2.37% NewShares held: Q3 2021 0, Q4 2021 0, Q1 2022 0, Q2 2022 167.5k
15 SYNDAX PHARMACEUTICALS INC COM SNDX SNDX 205,003 $3.9m2.21% 2.21% ReducedShares held: Q3 2021 206.1k, Q4 2021 206.1k, Q1 2022 206.1k, Q2 2022 205.0k -1.1k -1,123 -0.5%
16 HEALTH SCIENCES ACQ CORP 2 ORD SHS OBIO OBIO 392,500 $3.9m2.19% 2.19% UnchangedShares held: Q3 2021 392.5k, Q4 2021 392.5k, Q1 2022 392.5k, Q2 2022 392.5k
17 MERUS N V COM MRUS MRUS 154,000 $3.5m1.95% 1.95% ReducedShares held: Q3 2021 122.0k, Q4 2021 235.5k, Q1 2022 235.5k, Q2 2022 154.0k -81.5k -81,500 -34.6%
18 PRECISION BIOSCIENCES INC COM COM 2,050,359 $3.3m1.83% 1.83% NewShares held: Q3 2021 0, Q4 2021 0, Q1 2022 0, Q2 2022 2.1m
19 UNITED THERAPEUTICS CORP DEL COM UTHR UTHR 13,000 $3.1m1.71% 1.71% NewShares held: Q3 2021 3.0k, Q4 2021 0, Q1 2022 0, Q2 2022 13.0k
20 HORIZON THERAPEUTICS PUB L SHS HZNP HZNP 35,888 $2.9m1.60% 1.60% AddedShares held: Q3 2021 0, Q4 2021 0, Q1 2022 33.2k, Q2 2022 35.9k +2.7k +2,688 8.1%
21 MILESTONE PHARMACEUTICALS IN COM MIST MIST 457,200 $2.8m1.57% 1.57% AddedShares held: Q3 2021 0, Q4 2021 0, Q1 2022 380.0k, Q2 2022 457.2k +77.2k +77,200 20.3%
22 VIRIDIAN THERAPEUTICS INC COM VRDN VRDN 234,026 $2.7m1.51% 1.51% ReducedShares held: Q3 2021 135.8k, Q4 2021 318.0k, Q1 2022 340.0k, Q2 2022 234.0k -106.0k -105,974 -31.2%
23 ACLARIS THERAPEUTICS INC COM ACRS ACRS 192,835 $2.7m1.51% 1.51% ReducedShares held: Q3 2021 140.8k, Q4 2021 98.0k, Q1 2022 217.6k, Q2 2022 192.8k -24.8k -24,765 -11.4%
24 GH RESEARCH PLC ORDINARY SHARES GHRS GHRS 243,250 $2.4m1.36% 1.36% ReducedShares held: Q3 2021 393.2k, Q4 2021 419.6k, Q1 2022 419.6k, Q2 2022 243.2k -176.4k -176,382 -42.0%
25 EYEPOINT PHARMACEUTICALS INC COM NEW EYPT EYPT 303,396 $2.4m1.34% 1.34% ReducedShares held: Q3 2021 369.9k, Q4 2021 243.1k, Q1 2022 307.9k, Q2 2022 303.4k -4.5k -4,548 -1.5%
26 ARROWHEAD PHARMACEUTICALS IN COM ARWR ARWR 61,926 $2.2m1.22% 1.22% ReducedShares held: Q3 2021 121.5k, Q4 2021 105.5k, Q1 2022 82.5k, Q2 2022 61.9k -20.6k -20,574 -24.9%
27 PMV PHARMACEUTICALS INC COM PMVP PMVP 152,500 $2.2m1.22% 1.22% AddedShares held: Q3 2021 0, Q4 2021 0, Q1 2022 135.5k, Q2 2022 152.5k +17.0k +17,000 12.6%
28 REZOLUTE INC COM NEW RZLT RZLT 645,136 $2.1m1.17% 1.17% NewShares held: Q3 2021 0, Q4 2021 0, Q1 2022 0, Q2 2022 645.1k
29 IOVANCE BIOTHERAPEUTICS INC COM IOVA IOVA 154,356 $1.7m0.95% 0.95% AddedShares held: Q3 2021 374.5k, Q4 2021 180.0k, Q1 2022 118.9k, Q2 2022 154.4k +35.5k +35,500 29.9%
30 PYXIS ONCOLOGY INC COMMON STOCK PYXS PYXS 645,149 $1.5m0.86% 0.86% AddedShares held: Q3 2021 0, Q4 2021 677.8k, Q1 2022 200.0k, Q2 2022 645.1k +445.1k +445,149 222.6%
31 VENTYX BIOSCIENCES INC COM VTYX VTYX 122,000 $1.5m0.83% 0.83% AddedShares held: Q3 2021 0, Q4 2021 0, Q1 2022 70.9k, Q2 2022 122.0k +51.1k +51,123 72.1%
32 ENANTA PHARMACEUTICALS INC COM ENTA ENTA 27,500 $1.3m0.73% 0.73% AddedShares held: Q3 2021 0, Q4 2021 0, Q1 2022 2.3k, Q2 2022 27.5k +25.2k +25,200 1095.7%
33 ITEOS THERAPEUTICS INC COM ITOS ITOS 62,000 $1.3m0.71% 0.71% NewShares held: Q3 2021 0, Q4 2021 0, Q1 2022 0, Q2 2022 62.0k
34 ACADIA PHARMACEUTICALS INC COM ACAD ACAD 71,500 $1.0m0.56% 0.56% NewShares held: Q3 2021 0, Q4 2021 0, Q1 2022 0, Q2 2022 71.5k
35 FULCRUM THERAPEUTICS INC COM FULC FULC 200,000 $980.0k0.55% 0.55% UnchangedShares held: Q3 2021 322.5k, Q4 2021 200.0k, Q1 2022 200.0k, Q2 2022 200.0k
36 GOSSAMER BIO INC COM GOSS GOSS 32,000 $268.0k0.15% 0.15% NewShares held: Q3 2021 215.0k, Q4 2021 119.8k, Q1 2022 0, Q2 2022 32.0k
37 VERASTEM INC COM COM 200,000 $232.0k0.13% 0.13% ReducedShares held: Q3 2021 2.0m, Q4 2021 1.9m, Q1 2022 997.0k, Q2 2022 200.0k -797.0k -796,951 -79.9%
38 SPRINGWORKS THERAPEUTICS INC COM SWTX SWTX 5,000 $123.0k0.07% 0.07% NewShares held: Q3 2021 0, Q4 2021 0, Q1 2022 0, Q2 2022 5.0k
39 TREVI THERAPEUTICS INC COM TRVI TRVI 35,000 $98.0k0.05% 0.05% NewShares held: Q3 2021 0, Q4 2021 0, Q1 2022 0, Q2 2022 35.0k
40 OCULAR THERAPEUTIX INC COM OCUL OCUL 13,171 $53.0k0.03% 0.03% NewShares held: Q3 2021 0, Q4 2021 0, Q1 2022 0, Q2 2022 13.2k
41 NUVATION BIO INC *W EXP 07/07/202 NUVB.WS NUVB.WS 90,832 $25.0k0.01% 0.01% NewShares held: Q3 2021 90.8k, Q4 2021 0, Q1 2022 0, Q2 2022 90.8k

Sold out since Q1 2022

SecurityTickerShares held beforeValue then
JOUNCE THERAPEUTICS INC JNCE JNCE 813,500 $5.5m813.5k shares
AVADEL PHARMACEUTICALS PLC 580,000 $4.0m580.0k shares
HARPOON THERAPEUTICS INC 497,500 $2.5m497.5k shares
ATHIRA PHARMA INC 140,030 $1.9m140.0k shares
MOLECULAR TEMPLATES INC 307,125 $1.1m307.1k shares
DICE THERAPEUTICS INC 37,500 $717.0k37.5k shares
IMMUNOGEN INC IMGN IMGN 55,000 $262.0k55.0k shares
SEELOS THERAPEUTICS INC 295,896 $248.0k295.9k shares
NUVATION BIO INC NUVB NUVB 90,832 $69.0k90.8k shares

Options (notional value)

UnderlyingTickerTypeShares controlled NotionalChange
AC IMMUNE SA Call Call 100,000 $354.0k100.0k shares New
ATHIRA PHARMA INC Call Call 100,000 $340.0k100.0k shares New

Stakes above 5%

Companies where this manager has reported owning more than 5% of a class of shares, on Schedule 13D (may seek influence) or 13G (passive): its latest filing for each, from 19 Dec 2024 on.

CompanyTickerStakeChange ScheduleLast filed
AADI BIOSCIENCE INC WHWK · 13D · filed 2026-05-18 WHWK 9.0%≈ $22.2m +1.2 pts 13D 2026-05-18